Lipid-lowering medications. HMG-CoA reductase inhibitors. Rosuvastatin.
The drug reduces elevated levels of LDL cholesterol (LDL-C), total cholesterol and triglycerides (TG) and increases the level of high-density lipoprotein cholesterol (HDL-C). It also reduces the level of apoliprotein B (apoB), non-HDL-C, HDL-C, TB-LDL and increases the level of apoliprotein A-1 (apoA-I). The drug also reduces the ratio of LDL-C / HDL-C, total cholesterol / HDL-C, non-HDL-C / HDL-C and the apoB / apoA-I ratio.
Treatment of hypercholesterolemia
For adults and children over 10 years of age with primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia) or mixed dyslipidemia (type IIb) as an adjunct to the diet when the diet and the use of other non-drug products (e.g. exercise, weight loss) are insufficient.
In homozygous familial hypercholesterolemia as an adjunct to the diet and other lipid-lowering treatments (e.g., LDL apheresis) or when such treatment is inappropriate.
Prevention of cardiovascular disorders
Prevention of significant cardiovascular disorders in patients at high risk of the first case of cardiovascular disorders, as an adjunct to the correction of other risk factors.
Before starting the treatment, the patient should be prescribed a standard cholesterol-lowering diet, which must be followed during the treatment. The dose should be selected individually depending on the purpose of the therapy and the patient’s response to the treatment, taking into account current recommendations.
The drug may be taken at any time of day, without regard to the timing of food.